越婢加半夏汤对急性加重期慢阻肺(痰热郁肺证)患者的应用效果  

The application effect of Yuebi plus Banxia decoction on patients with chronic obstructive pulmonary disease(Phlegm-heat syndrome of stagnation lung)in acute exacerbation period

作　　者：张莲花 高向坤 马新峰 史云海 ZHANG Lianhua;GAO Xiangkun;MA Xinfeng;SHI Yunhai(Department of Respiratory Medicine,Xiangcheng Traditional Chinese Medicine Hospital,Xiangcheng 466200,China)

机构地区：[1]项城市中医院呼吸科,河南项城466200

出　　处：《黑龙江医药科学》2025年第3期74-77,共4页Heilongjiang Medicine and Pharmacy

基　　金：河南省自然科学基金项目,编号:2020070。

摘　　要：目的:评估越婢加半夏汤联合西医常规治疗应用在慢阻肺急性加重期(AECOPD)痰热郁肺证患者中的效果。方法:选取2019年7月至2022年7月河南省项城市中医院收治的106例痰热郁肺证AECOPD患者展开研究,随机数字表法分为对照组与观察组各53例,对照组行西医常规治疗,观察组加用越婢加半夏汤治疗,评价组间临床有效率、中医症状积分、慢性阻塞性肺疾病评估测试CAT、6 min步行试验(6MWT)、肺通气指标、血清炎性因子、安全性。结果:(1)较之对照组86.79%,观察组临床有效率98.11%更高(P<0.05);(2)治疗前,组间中医症状积分、CAT、6MWT、肺通气指标[用力肺活量(FVC)、最大呼气流量(MEF)、第1秒用力呼气容积(FEV1)]、血清炎性因子[C反应蛋白(CRP)、转化生长因子-β1(TGF-β1)、肿瘤坏死因子-α(TNF-α)]无差异(P>0.05);治疗10 d后,观察组中医症状积分、CAT、血清炎性因子(CRP、TGF-β1、TNF-α)更低,6MWT更远,肺通气指标(FVC、MEF、FEV1)更高(P<0.05);(3)在用药安全性方面,观察组1.89%与对照组7.55%无差异(P>0.05)。结论:对痰热郁肺证AECOPD患者实施越婢加半夏汤联合西医常规治疗,能够增强疗效,降低中医症状积分、CAT评分,缓解炎症反应,改善肺功能,提高运动耐力,安全性高。Objective:To evaluate the efficacy of Yuebi plus Banxia decoction combined with conventional Western medicine treatment in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)with syndrome of phlegm-heat stagnation of lung.Methods:106 AECOPD patients with phlegm heat stagnation lung syndrome from Xiangcheng Traditional Chinese Medicine Hospital in Henan Province were selected and divided into control group and observation group,with 53 patients in each group using the random number table method.The control group received conventional Western medicine treatment,while the observation group received additional Yuebi plus Banxia decoction treatment.The clinical efficacy,Traditional Chinese Medicine symptom scores,COPD Assessment Test(CAT)scores,6-minute walk test(6MWT)results,lung ventilation indicators,serum inflammatory factors and safety were evaluated between the groups.Results:(1)The clinical efficacy rate in the observation group 98.11%was higher than that in the control group 86.79%(P<0.05);(2)Before treatment,there were no significant differences in Traditional Chinese Medicine symptom scores,CAT scores,6MWT results,lung ventilation indicators[forced vital capacity(FVC),maximal expiratory flow(MEF),forced expiratory volume in one second(FEV1)],and serum inflammatory factors[C-reactive protein(CRP),transforming growth factor-β1(TGF-β1),tumor necrosis factor-α(TNF-α)]between the two groups(P>0.05);After 10 days of treatment,the observation group had lower Traditional Chinese Medicine symptom scores,CAT scores and serum inflammatory factors(CRP,TGF-β1,TNF-α),a longer 6MWT distance,and higher lung ventilation indicators(FVC,MEF,FEV1)(P<0.05);(3)In terms of medication safety,there was no significant difference between the observation group 1.89%and the control group 7.55%(P>0.05).Conclusion:The application of Yuebi plus Banxia decoction combined with conventional Western medicine treatment in AECOPD patients with syndrome of phlegm-heat stagnation of lung can enhance efficacy,red

关 键 词：越婢加半夏汤 西医常规治疗 慢阻肺 急性加重期 痰热郁肺证 中医症状积分 CAT评分 

分 类 号：R259[医药卫生—中西医结合]